ContraFect Hires David Huang, M.D., Ph.D. as Chief Medical Officer
November 15, 2011 09:13 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwire - Nov 15, 2011) - ContraFect Corporation, the company that is pioneering the use of recombinant proteins for the treatment of drug-resistant bacteria, announced today that...
ContraFect Announces Agreement With The Rockefeller University for New Staph Lysin
September 21, 2011 09:13 ET
|
ContraFect Corporation
NEW YORK, NY--(Marketwire - Sep 21, 2011) - ContraFect Corporation, the company that is pioneering the use of recombinant proteins for the treatment of drug-resistant bacteria, announced that it...
ContraFect Announces Appointment of Sol Barer to Board of Directors
February 22, 2011 09:12 ET
|
ContraFect Corporation
NEW YORK, NY--(Marketwire - February 22, 2011) - ContraFect Corporation announced today that Sol Barer, Ph.D. has joined the company's Board of Directors. Dr. Barer has been the principal...
CEO Robert Nowinski Announces ContraFect Leases Laboratory and Office Space
December 14, 2010 09:12 ET
|
ContraFect Corporation
NEW YORK, NY--(Marketwire - December 14, 2010) - ContraFect Corporation, the Company that is pioneering the use of Monoclonal Antibodies and Lysins for the treatment of life-threatening infectious...
ContraFect CEO Robert Nowinski Announces Agreement With The Rockefeller University to Commercialize Eight Patents Covering Bacterial Treatments
November 18, 2010 09:12 ET
|
ContraFect Corporation
NEW YORK, NY--(Marketwire - November 18, 2010) - ContraFect Corporation, the company that is pioneering the use of recombinant proteins for the treatment of drug resistant bacteria, announced that it...
ContraFect Completes $14 Million Financing
October 26, 2010 09:12 ET
|
ContraFect Corporation
NEW YORK, NY--(Marketwire - October 26, 2010) - ContraFect Corporation, the company that is pioneering the use of monoclonal antibodies and lysins for the treatment of life-threatening...